1 Broadway # 14, Cambridge, MA 02142

SynDevRx brings new tools and fresh thinking to cancer treatment.

We’re developing novel treatments directed specifically towards cancer patients that also have baseline metabolic complications (overweight/obesity, pre-diabetes, T2D). Research shows that improving cancer patients’ metabolic state improves outcomes, but it’s a challenge!

By offering treating oncologists and physicians a simple once-every-two-week subcutaneous injection to their patients that address a major unmet medical need (baseline metabolic dysfunction) we hypothesize we can potentiate standard-of-care treatments for a wide variety of cancers, including breast, prostate, colorectal, liver among others.

Our drug development strategy has three-parts:
1. start with a validated class of drug that has demonstrated clinical activity in cancer and obesity – but had a toxicity problem;
2. tackle the toxicity issues while maintaining drug activity via polymer-drug conjugation; and
3. improve the doctor and patient experience by delivering this new drug on a simple Q14D basis with relatively low volume of infusion.

oncologist measuring obese patient


The link between metabolic dysfunction and cancer outcomes is undeniable. SynDevRx is the leader in the emerging metabo-oncology field of drug development, and our first clinical drug candidate targets a patient population that comprises millions of new cancer cases around the world each year. Learn about metabo-oncology, the newest addition to the armamentarium of cancer treatment.


Polymer-Drug Conjugation

In 1975, Helmut Ringsdorf first suggested that attaching active small molecules to biocompatible polymers could improve drug properties. Many companies have since come close to realizing his vision but failed. With our novel approach to polymer-drug conjugates, SynDevRx has uncovered the key to success. Learn about our polymer-drug conjugation approach.


MetAP2 – Validated in Cancer and in Obesity

The molecular target for our novel fumagillin-polymer conjugates — methionine aminopeptidase type II (MetAP2) — is a key mediator in various conditions related to hypoxia, cell cycle arrest, angiogenesis and chronic inflammation. See why MetAP2 inhibition could help in treating many cancer types, morbid obesity and other diseases.


Scientific Presentations

SDX-7320 Enhanced Activity in Models of Obesity-Driven Cancer (EO771 TNBC, B16F10 melanoma)

SDX-7320 Improves Tumor Immune Micro-Environment in TNBC Model (EO771)

SDX-7320 Shows Anti-Tumor Synergy and Improves Glucose Control with PI3K Inhibitor

SDX-7320 Phase 1 Safety Study Results: Improvements in Angiogenic and Metabolic Markers

SDX-7320 Enhances AKT Inhibitor Activity Via Suppression of Hypoxia- and Inflammatory-Related Genes

SDX-7320 Demonstrates Both Anti-Tumor and Anti-Diabetic Activity in Multiple Animal Models

Evexomostat (SDX-7320) Prepares Amelia-1 Study in Combination with PI3K Inhibitor Plus Fulvestrant

AACR 2023
Evexomostat (SDX-7320) Shows Potent Anti-Tumor, Anti-Angiogenic Activity in Multiple Models of Prostate Cancer